For Chemical Peels, Lean on Documentation and Medical Necessity
Question: An established 16-year-old patient presents to an outpatient dermatology office for worsening nodulocystic acne of the face and upper back after three months of topical benzoyl peroxide/clindamycin and oral doxycycline. The dermatologist documents increased painful cysts, early scarring, and poor response to therapy; reviews medication adherence and adverse effects; discontinues doxycycline; initiates oral isotretinoin after counseling the patient and parent regarding risks, monitoring, and pregnancy-prevention requirements; and schedules follow-up. During the same encounter, the dermatologist performs a medically directed superficial chemical peel of the face to treat active inflammatory acne. Which procedure codes should I report for this encounter? Florida Subscriber Answer: In this scenario, moderate medical decision making (MDM) may be supported by management of a chronic condition with exacerbation (worsening nodulocystic acne with early scarring) and prescription drug management, including discontinuation of doxycycline and initiation of isotretinoin, which requires risk counseling and ongoing monitoring. The evaluation and management (E/M) documentation should clearly reflect work related to the evaluation of disease progression, treatment failure, and systemic therapy decision-making, rather than elements inherent to performing the chemical peel. In that case, report 99214 (Office or other outpatient visit for the evaluation and management of an established patient, level 4; modifier 25, Significant, separately identifiable evaluation and management service by the same physician or other qualified healthcare professional on the same day of the procedure or other service) appended with modifier 25 (Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service) if the documentation supports a significant, separately identifiable E/M service with moderate MDM in addition to the same-day procedure. Modifier 25 is appropriate only when the E/M service exceeds the usual preprocedure evaluation associated with the peel. Report the chemical peel separately using the CPT® code that reflects the depth and anatomic site. One option might be 15788 (Chemical peel, facial; epidermal), if documentation supports a superficial facial peel. Payer coverage may vary for chemical peels used to treat acne, as they may be considered cosmetic or not medically necessary, so it’s important to verify payer policy before billing. Documentation should clearly distinguish the E/M service (disease status, management decisions, isotretinoin counseling, and follow-up plan) from the procedure note (agent, site, depth, consent, and post-procedure care). Rachel Dorrell, MA, MS, CPC-A, CPPM, Production Editor, AAPC
